rabies immune globulin, human (RIG) (HyperRAB, HyperRAB S/D, Imogam, Imogam Rabies HT, Imovax Rabies, RIG)
Classes: Immune Globulins
Dosing and uses of HyperRAB, HyperRAB S/D (rabies immune globulin, human (RIG))
Adult dosage forms and strengths
injectable solution
- 150 International Units/mL (2mL vial)
- 150 International Units/mL (10mL vial)
Rabies, Postexposure Prophylaxis
20 International Unit/kg, infiltrate locally around bite
If full dose infiltration not possible, give rest IM in gluteal or lateral thigh muscle
Administration
Because of injury risk to sciatic nerve, avoid central gluteal region; administer only in upper, outer quadrant
Always administer in conjunction with rabies vaccine (HDCV)
Preferably give concomitantly with vaccine but may be given thru 7th day after first dose of vaccine
Avoid repeated dose once vaccine treatment has started
Other Information
Give with 1st dose of vaccine as soon as possible post-exposure
Pediatric dosage forms and strengths
injectable solution
- 150 International Units/mL (2mL vial)
- 150 International Units/mL (10mL vial)
Same as adult dosing; 20 International Unit/kg, infiltrate locally around bite
HyperRAB, HyperRAB S/D (rabies immune globulin, human (RIG)) adverse (side) effects
Frequency not defined
Injection site pain
N/V
Fever
Lethargy
Chest tightness
Rash
Headache
Anaphylaxis
Angioneurotic edema
Nephrotic syndrome (rare)
Warnings
Contraindications
None
Cautions
Thrombocytopenia, bleeding disorders, or prior allergic reactions to immune globulins
Avoid live vaccinations for 3 mth
Do NOT give IV
Discard unused portions
Pregnancy and lactation
Pregnancy category: C
Lactation: no adverse events reported; may be excreted in breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of HyperRAB, HyperRAB S/D (rabies immune globulin, human (RIG))
Half-Life: 21 d
Peak Plasma Time: 2-13 d
Mechanism of action
Human immune globulins from donors
